Trials
Search / Trial NCT06433063

Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment

Launched by CIGDEM SOYDAL · May 25, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how low oxygen levels in tumors, known as hypoxia, might affect the success of a specific treatment for prostate cancer called Lu-177 PSMA therapy. Researchers will use a special imaging technique called 18F-FMISO PET to measure and understand the levels of hypoxia in patients’ tumors before they receive treatment. This information could help improve treatment outcomes, as tumors with low oxygen levels often do not respond well to therapies.

The trial is looking for men aged 18 and older who have been diagnosed with prostate cancer and are eligible for Lu-177 PSMA treatment. However, individuals with a life expectancy of less than three months or certain health issues may not be able to participate. If you join the study, you will undergo imaging to assess your tumor's oxygen levels, and this could provide valuable information for your treatment plan. The trial is currently recruiting participants, so it's a good opportunity for those who qualify to contribute to important research in prostate cancer treatment.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • • over 18 years old
  • • Patients diagnosed with prostate cancer who were referred to our clinic for Lu-177 PSMA treatment and were found suitable for treatment
  • Exclusion Criteria:
  • • Has a life expectancy of less than 3 months
  • • ECOG\>2
  • • contraindication for radionuclide treatment with Lu-177 PSMA

About Cigdem Soydal

Cigdem Soydal is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization collaborates with a network of experienced professionals and institutions to conduct rigorous clinical studies. Cigdem Soydal emphasizes adherence to ethical standards and regulatory compliance, ensuring the safety and efficacy of new therapies. Through strategic partnerships and a patient-centered approach, the sponsor aims to facilitate the development of groundbreaking treatments across various therapeutic areas.

Locations

Ankara, , Turkey

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0